Search Results 461-470 of 17197 for egfr

1. A Study to Evaluate Agents to Treat Moderately or Severely Ill Patients with Severe Acute Respiratory Syndrome Coronavirus 2 - Mayo Clinic

   Estimated glomerular filtration rate (eGFR) < 30 mL/min (including patients receiving hemodialysis or hemofiltration). Neutropenia (absolute neutrophil ...

2. A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab with or without Chemotherapy or Lenvatinib (E7080/MK 7902) in Subjects with Advanced Solid Tumors - Mayo Clinic

   Subjects eligible to receive EGFR-targeted therapy must have previously received this treatment in order to be eligible for the study. Note – Subjects with ...

3. Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) - Mayo Clinic

   filtration rate(eGFR) < 45 mL/min). 4. Overlap syndromes, systemic lupus erythematosus with anti-double-stranded deoxyribonucleic acid antibody ...

4. A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients with CAA - Mayo Clinic

   Estimated glomerular filtration (eGFR) of <30mL/min/1.73m2 (calculation will be based on the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] ...

5. A Global Phase III Study Of Rilvegostomig Or Pembrolizumab Plus Chemotherapy For First-Line Treatment Of Metastatic Non-squamous NSCLC - Mayo Clinic

   * Absence of sensitizing EGFR mutations (including, but not limited to, exon 19 deletion and exon 21 L858R, exon 21 L861Q, exon 18 G719X, and exon 20 S768I ...

6. RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC - Mayo Clinic

   Epidermal growth factor receptor (EGFR) or vascular endothelial growth factor receptor (VEGFR) directed therapies are allowed as part of the previous ...

7. A Study of AO-176 as Monotherapy Combinated with Bortezomib and Dexamethasone in Adults with Relapsed or Refractory Multiple Myeloma - Mayo Clinic

   eGFR (CKD-EPI calculation) ≥ 30 mL/min/1.73m^2. Hepatic: Serum total bilirubin ≤ 1.5 x ULN; or; Direct bilirubin ≤ ULN for patients with total bilirubin ...

8. Extension Study Of ACT-EARLY - Mayo Clinic

   Stage IV or V chronic kidney disease (corresponding to an eGFR ≤ 29 mL/min/1.73 m2), or undergoing renal dialysis, or recipient of a kidney transplant.

9. Laryngeal (Voice Box) Cancer Clinical Trials - Mayo Clinic Research

   The purpose of this study is to demonstrate the safety and tolerability of JAB-3312 in combination with anti-PD-1 mAb or MEKi or KRASi or EGFR-TKI in patients ...

10. CLIP-IT Post Market Study: Exclusion of the Left Atrial Appendage With Penditure™ - Mayo Clinic

    * Chronic Kidney Disease Stage IV or V (eGFR \<30 ml/min) * NYHA Class IV heart failure symptoms * Patient has a documented history of substance (drug or ...